Deutsche Bank AG purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 164,813 shares of the biopharmaceutical company's stock, valued at approximately $5,503,000. Deutsche Bank AG owned about 0.17% of Ultragenyx Pharmaceutical as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Assenagon Asset Management S.A. lifted its stake in shares of Ultragenyx Pharmaceutical by 1,030.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company's stock valued at $47,298,000 after acquiring an additional 2,057,951 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock valued at $65,205,000 after acquiring an additional 1,864,164 shares during the period. Norges Bank bought a new position in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $29,004,000. Eagle Health Investments LP bought a new position in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $18,522,000. Finally, Millennium Management LLC increased its stake in Ultragenyx Pharmaceutical by 787.6% in the 4th quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company's stock worth $20,255,000 after purchasing an additional 781,431 shares during the period. 97.67% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have weighed in on RARE shares. Weiss Ratings upgraded Ultragenyx Pharmaceutical from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 9th. Barclays cut their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating on the stock in a report on Wednesday, April 29th. Cantor Fitzgerald lifted their target price on shares of Ultragenyx Pharmaceutical from $96.00 to $103.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. Morgan Stanley upped their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the company an "overweight" rating in a report on Friday. Finally, Wells Fargo & Company increased their price target on shares of Ultragenyx Pharmaceutical from $45.00 to $46.00 and gave the company an "overweight" rating in a research report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $58.89.
View Our Latest Analysis on RARE
Ultragenyx Pharmaceutical Stock Performance
RARE opened at $25.72 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.29 and a 52-week high of $39.89. The stock has a market capitalization of $2.54 billion, a PE ratio of -4.40 and a beta of 0.35. The stock's 50 day moving average price is $28.59 and its 200-day moving average price is $24.98.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.32. The business had revenue of $214.00 million for the quarter, compared to analysts' expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm's revenue for the quarter was up 28.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.17) earnings per share. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.03 EPS for the current fiscal year.
Insider Transactions at Ultragenyx Pharmaceutical
In related news, CFO Howard Horn sold 4,653 shares of the business's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $23.77, for a total transaction of $110,601.81. Following the transaction, the chief financial officer owned 105,689 shares in the company, valued at $2,512,227.53. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the transaction, the executive vice president directly owned 94,462 shares of the company's stock, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 8,552 shares of company stock valued at $207,455. Company insiders own 5.20% of the company's stock.
Ultragenyx Pharmaceutical Profile
(
Free Report)
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.
While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
